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This is a double-blind, placebo-controlled study of the efficacy, safety, and tolerability of sibutramine in the management
of obese patients for a 6-month period.
METHOD: Sixty-one obese patients (BMI >30, <40 kg/m2), aged 18-65 years were evaluated. In the first phase of the
study (30 days), the patients were given a placebo. We monitored compliance with a low-calorie diet (1200 kcal/day) and to
the placebo. In the next stage, the double-blind phase (6 months), we compared placebo and sibutramine (10 mg/day). The
criteria for evaluating efficacy were weight loss, reduction in body mass index (BMI), and abdominal and hip circumferences.
Tolerability was assessed based on reported side effects, variation in arterial blood pressure and heart rate, metabolic profile
(fasting glucose, total cholesterol and its fractions, and triglycerides), laboratory tests (renal and hepatic functions), and
flow Doppler echocardiogram.
RESULTS: We observed a greater weight loss (7.3 kg, 8% vs 2.6 kg, 2.8%) and a reduction in body mass index (7.4% vs
2.1%) in the sibutramine group than in the placebo group. Classifying the patients into 4 subgroups according to weight loss
(weight gain, loss <5%, loss of 5% to 9.9%, and loss >10%), we observed a weight loss of >5% in 40% of the patients on
sibutramine compared with 12.9% in the placebo group. We also detected weight gain in 45.2% of the placebo group
compared to 20% in the sibutramine group. The sibutramine group showed improvement in HDL- cholesterol values (increased
by 17%) and triglyceride values (decreased by 12.8%). This group also showed an increase in systolic blood pressure (6.7%,
5 mmHg). There were no changes in echocardiograms comparing the beginning and end of follow-up, and side effects did
not lead to discontinuation of treatment.
DISCUSSION: Sibutramine proved to be effective for weight loss providing an 8% loss of the initial weight. Compliance
to prolonged treatment was good, and side effects did not result in discontinuation of treatment. These data confirmed the
good efficacy, tolerability, and safety profiles of sibutramine for treatment of obesity.
DESCRIPTORS:  Obesity.  Weight loss.  Sibutramine.
Prevalence of obesity and its
comorbidities has increased all over the
world1-3. Abdominal or visceral obesity
is closely related to hypertension, glu-
cose intolerance, hypertriglyceridemia
with low HDL levels, and hyperinsuline-
mia, resulting in the so-called “metabolic
syndrome” with an increased risk of car-
diovascular disease4-7. Obesity is also
a risk factor for sleep apnea, orthope-
dic, dermatological and thromboembo-
lic conditions, and some types of can-
cer8-9. In addition, excessive weight is a
discriminating factor in the workplace
and in society as a whole.
Today there is strong evidence that
weight loss in overweight and obese
subjects reduces cardiovascular risk
factors10. Weight loss may be achieved
through low-calorie diet, physical exer-
cise, medication, and surgery, or as a
combination of this management11-12.
Drug treatment, associated with
changes in dietary habits and physical
exercise, has been shown to be effec-
tive, increasing compliance to treatment
and resulting in satisfactory weight
loss.
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Sibutramine is a tertiary amine ini-
tially developed as an antidepressant
medication. Subsequent studies
showed a significant effect of the drug
on weight loss due to its satietogenic
and calorigenic effects13-15.
The objective of the present study
was to evaluate the efficacy, safety, and
tolerability of sibutramine in obese pa-
tients over a 6-month period and to
check the influence of the drug on the
echocardiographic patterns of the pa-
tients. We considered effective weight
loss to be a reduction by a minimum of
5% of the initial weight.
PATIENTS  AND  METHODS
From May 1998 to September 1999,
we recruited 61 patients (60 female and
1 male), aged 18-65 years and with a
body mass index (BMI) >30 kg/m2. The
study was divided into 2 phases: the
first phase (30 days) with the placebo,
and the second phase (6 months) evalu-
ating  sibutramine vs placebo.
The inclusion criteria were fasting
glucose values <130 mg/dL, total cho-
lesterol <300 mg/dL, triglycerides <500
mg/dL, uric acid <8.0 mg/dL, trans-
amines <40 mg/dL, bilirubin <2.0 mg/
dL, urea <40 mg/dL, and creatine < 1.5
mg/dL. Echocardiographic studies were
also performed in this phase by means
of a  System Five, Ving Med, with color
flow mapping able to generate and re-
ceive second harmonic echoes and syn-
chronized firing of EKG. All
echocardiographs were performed by
the same observer (NH).
The exclusion criteria were weight
loss in the previous 3 months, chronic
diseases, such as renal or hepatic fail-
ure, endocrinopathy, cardiopathy, se-
vere hypertension (systolic blood pres-
sure >150 mmHg, diastolic blood pres-
sure >110 mmHg), severe dyslipidemia
(total cholesterol >300 mg/dL and trig-
lycerides >500 mg/dL), rheumatic, gas-
trointestinal, respiratory, neurological,
and psychiatric disorders. Patients with
an altered echocardiogram or taking
beta-blockers, dopaminergic agonists,
antidepressant agents, or thyroid hor-
mones were also excluded. Women of
childbearing age were instructed on
how to use the appropriate contracep-
tive method.
In the first phase, the patients were
clinically assessed and weighed (scale
brand, Filizola) without shoes and wear-
ing light clothes. Height was deter-
mined using a wooden stadiometer. BMI
was calculated dividing weight (kg) by
height (m2). Systolic and diastolic blood
pressure levels were measured with
patients in the seated position, on the
left arm, and after a 5-minute rest pe-
riod.16 The parameter used to measure
the abdominal circumference was the
shortest diameter between the lowest
rib and the iliac crest of the subject in
orthostatic position. In order to mea-
sure the hip circumference, the greater
trochanter region was used17. During
the first 30 days, the patients received
placebo once a day (only the physi-
cians had this information) at breakfast
and were told to follow a low-calorie
diet (1200 kcal/day) composed of 55%
carbohydrates, 30% fat, and 15% pro-
tein. They were also encouraged to prac-
tice 30-60 minutes of physical activity
every day.
Thirty days later, the patients were
randomized into 2 groups: one group
received sibutramine 10 mg/day and the
other group received the placebo, to be
taken at breakfast. The placebo tablets
were obtained from Knoll Pharmaceuti-
cal Industries and were rigorously iden-
tical to the sibutramine tablets.
The patients were followed up for 6
months. During the monthly appoint-
ments, the efficacy criteria were re-
viewed: weight and height, abdominal
and hip circumference, tolerability
(variations in arterial blood pressure,
and heart rate), and safety (possible
adverse effects of the drug). Labora-
tory tests were repeated at months 4
and 6, and an echocardiogram was re-
peated at the end of the study.
All patients signed the informed
consent statement after being in-
structed about the study details, the
Ethics Committee of the University
Hospital approved the protocol.
The Student’s t test was used to
compare means in the statistical analy-
sis. To compare results from the initial
and final phases, as well as different
weight loss percentiles, we used the
chi-square test. The significance level
was P < 0.0518.
RESULTS
Out of 61 patients selected, 46 con-
cluded the study. The mean age was
38.3 years for the sibutramine and pla-
cebo groups. The data for patients as-
sessed during the first and last visits
(height, weight, waist, and hip mea-
sures, BMI, systolic and diastolic blood
pressure, heart rate, and laboratory
tests) are presented in table 1.  The
sibutramine and placebo groups had
similar initial clinical and laboratory pro-
files.
Fifteen patients (24.6%) withdrew
treatment; 7 were in the sibutramine
group (7/30 - 23.3%), and 8 in the pla-
cebo group (8/31 - 25.8%). Dropout from
study was not a result of side effects of
the drug.
In the analysis of efficacy, the per-
centage reduction in weight (8%) and
BMI (7.4%) was greater in the
sibutramine group than in the placebo
group (2.8% and 2.1%, respectively).
The sibutramine group  lost an average
of 7.3 kg vs 2.6 kg in the placebo group.
Reduction in BMI was the only statis-
tically significant variable (P < 0.002).
Classifying weight loss into 4 sub-
groups (weight gain, loss <5%, loss of
5% to 9.9%, and loss >10%), we ob-
served a weight loss of >5% in 40% of
the patients from the sibutramine group
as compared to 12.9% in the placebo
group. On the other hand, 45.2% of the
patients gained weight in the placebo
group as compared with 20% in the
sibutramine group (Table 2). Although
the sibutramine group had better results
than placebo group, these differences
were not statistically significant, except
in the weight gain group.
The abdominal circumference
(AC) and hip circumference (HC) val-
ues showed a reduction of 7% (mean
of 7.3 cm) and 5% (6.2 cm), respectively
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in the sibutramine group, and there was
a reduction of 3% (3.5 cm) in both val-
ues in the placebo group (Table 1).
These differences in both groups were
not statistically significant.
Regarding blood pressure, we ob-
served increased systolic pressure val-
ues in both groups and with the same
variation (5 mmHg). Diastolic pressure,
however, increased only in the
sibutramine group (5 mmHg). Concern-
ing the lipid profile (total cholesterol
and LDL-cholesterol) and glucose lev-
els, the values remained unaltered in
both groups. There was an improve-
ment in HDL-cholesterol (increase of
17%) and triglyceride levels (decrease
of 12.8%) in the group treated with
sibutramine (Table 1). There was no sta-
tistically significant difference between
these variables between sibutramine
and placebo groups.
Tolerability and safety results re-
vealed that  5 patients in the
sibutramine group and 10 patients in
the placebo group reported side ef-
fects. None of them discontinued treat-
ment because of side effects. The most
common side effects were intestinal
constipation and dry mouth. Despite
the higher incidence of side effects in
the placebo group, there was no sta-
tistically significant difference be-
tween the groups (P > 0.05) table 3.
In the initial assessment of 61 pa-
tients, 40 (65.5%) of them had a normal
echocardiogram, and 21 patients
showed slight alterations with no he-
modynamic impact (Table 4). Six
months later, there was no alteration in
the echocardiographic patterns in either
group.
DISCUSSION
Obesity is an important risk factor
for morbidity and mortality. There is
evidence that weight loss leads to re-
duced risk of morbidity and mortality.
In the obese patients assessed in
this study, the administration of
sibutramine resulted in better results
than administration of placebo in pa-
tients undergoing diet restriction and
exercise programs (weight loss: 8% vs
2.8%; reduction in BMI: 7.4% vs 2.1%;
reduction in waist measure: 7% vs 3.1%).
However, only the difference in BMI
Table 1- Distribution of main variable means at the beginning and end of the study and variation observed during 6 months.
Variables Sibutramine Placebo
Initial Final variation/DP * Initial Final variation/DP
(n = 30) (n = 23) (n = 31) (n = 23)
Weight (kg) 91.1 83.8 ¯7.3 (8.0%) 91.5 88.9 ¯2.6(2.8%)
Height (cm) 157.8 157.4
Systolic blood pressure (mmHg) 124.3 129.1 ­4.8 (3.9%) 129.3 134.4 ­5.1(3.9%)
Diastolic blood pressure (mmHg) 79.1 84.4 ­5.3 (6.7%) 80.7 81.9 ­1.2 (1.5%)
Heart rate (bpm) 81.5 87.3 ­ 5.8 (7.1%) 82.6 86.8 ­4.2 (5%)
Abdominal (cm) 103.5 96.2 ¯7.3 (7.0%) 104.8 101.5 ¯3.3 (3.1%)
Hip (cm) 122.4 116.2 ¯6.2 (5.0%) 123.8 119.9 ¯3.9 (3.2%)
BMI (kg/m 2)** 36.6 33.9 ¯2.7 (7.4%) 36.9 36.1 ¯0.8 (2.1%)
Total-Cholesterol (mg/dL) 218.9 221.7 ­2.8 (1.2%) 213.8 211.9 ¯1.9 (0.8%)
HDL-C (mg/dL) 43.9 51.5 ¯7.6 (17.3%) 47.3 47.1
LDL-C (mg/dL) 147.1 147.2 141.0 138.1 ¯2.9 (2%)
Triglycerides (mg/dL) 141.6 123.4 ¯18.2 (12.8%) 113.3 126.6 ­13.3 (11.7%)
Glucose (mg/dL) 99.8 98.7 99.4 99.5
*DP – percentage difference.
**The initial and final BMI was the only variable that the difference was statistically significant (P < 0.002).
Table 2 - Comparative analysis of sibutramine and placebo by weight loss Subgroups.
Sibutramine Placebo
Number of patients/% Number of patients/%
Weight gain 6 (20%)* 14 (45.2%)
Loss <5% 12 (40%) 13 (41.9%)
Loss>5% - <10% 4 (13.3%) 3 (9.7%)
Loss >10% 8 (26.7%) 1 (3.2%)
*The chi-square test showed statistically significant difference in weight gain subgroups
(P <0.03).
Table 3 - Proportion of patients who experienced adverse effects during the 6-month
follow-up.
Adverse effects Sibutramine group (30) Placebo group (31)
Intestinal constipation 2 (6.6%) 5 (16.1%)
Dry mouth 2 (6.6%) 4 (12.9%)
Epigastralgia 0 1 (3.2%)
Somnolence 1 (3.3%) 0
Although the placebo group reported more adverse effects, there was no statistically significant
difference between the two groups (P > 0.05).
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was statistically significant. In addition,
the percentage of subjects who lost
>5% of their initial weight was mark-
edly higher in the sibutramine group
(40% vs 12.9% in the placebo group).
It should be emphasized that weight
loss ³5% results in evident reduction in
cardiovascular risks. In the patients who
did not have a marked metabolic risk
profile, we observed increased HDL lev-
els and reduced triglyceride levels with
the use of sibutramine.
Regarding tolerability, there was no
statistically significant difference be-
tween the two groups; side effects were
not severe, and no patient discontinued
treatment because of adverse effects.
Table 4- Analysis of echocardiographic results of patients before the study and
at the end of the 6-month test period.
Alterations found in the Number of Echocardiogram at the
first echocardiogram patient/frequency end of the study (6 months)
Normal 40 (65.5%) Unaltered
Mild valve thickening 4 (6.5%) Unaltered
Mild valvular regurgitation 8 (13.1%) Unaltered
Altered LV compliance 4 (6.5%) Unaltered
Mild valve thickening and 5 (8.2%) Unaltered
regurgitation
The slight increase in systolic blood
pressure (5 mmHg) and in diastolic
blood pressure (5 mmHg) in the
sibutramine group was corroborated by
the literature13-15. The slight increase in
blood pressure seems to be compen-
sated by drug-induced weight loss15. It
is also important to mention that in-
creased systolic blood pressure was
observed in the placebo group, but
there was no explanation for this fact.
We were particularly interested in
checking whether sibutramine would
cause valvular echocardiographic alter-
ations, as described in studies with
fenfluramine and D-fenfluramine21. The
echocardiographic study was very de-
tailed and was carried out with sophis-
ticated equipment. The analysis of find-
ings was made by the same observer.
Out of 61 patients, 21 had some previ-
ous echocardiographic alteration,
showing that heart disease may be dem-
onstrated in a significant percentage of
apparently healthy obese patients.
However, in the final assessment, we
did not identify any alterations in the
echocardiogram in either group. These
data were similar to those found in an-
other study 22 ,  demonstrating that
sibutramine does not have a dilation
effect on the heart.
Therefore, our results enabled us to
conclude that sibutramine is an effec-
tive drug for inducing reduction of the
body mass index and for preventing
weight gain in obese patients undergo-
ing low-calorie diet and exercise pro-
grams, and it has good safety and tol-
erability profiles.
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RESUMO RHCFAP/3077
HALPERN A e col. - Avaliação da
eficácia, segurança e tolerabilidade
da sibutramina em obesos - estudo
randomizado duplo-cego. Rev.
Hosp. Clín. Fac. Med. S. Paulo
57(3): 2002.
O presente estudo objetivou com-
parar a eficácia, segurança e
tolerabilidade da sibutramina em paci-
entes obesos.
MÉTODO: Selecionamos 61 pacien-
tes obesos (30<IMC<40kg/m2) entre 18-
65 anos. Na primeira fase do estudo (30
dias), os pacientes usaram medicação
placebo e realizaram os exames de in-
clusão, enquanto acompanhamos a
adesão à dieta hipocalórica prescrita
(1200cal/dia) e à medicação. A seguir,
na fase duplo-cega (6 meses), compara-
mos placebo vs sibutramina (10mg/dia).
Os critérios para a avaliação da eficácia
foram: perda de peso, diminuição do ín-
dice de massa corpórea (IMC), circunfe-
rência abdominal e de quadril. A avalia-
ção da tolerabilidade foi feita pelo relato
dos efeitos adversos, variações da pres-
são arterial, freqüência cardíaca, perfil
metabólico (glicemia de jejum, colesterol
total e frações e triglicerídeos), altera-
ções laboratoriais (função hepática e re-
nal) e pelo ecocardiograma com Doppler
fluxo realizado em todos os pacientes
no início e fim do tratamento.
RESULTADOS: Houve uma diminui-
ção maior de peso (7,3kg—8% vs 2,6kg—
2,8%) e IMC (7,4% vs 2,1%) no grupo
sibutramina do que no grupo placebo.
Quando dividimos a perda de peso em
quatro subgrupos (aumento de peso,
perda<5%, perda entre 5-9,9%, perda
>10%) ocorreu perda de peso>5% em 40%
dos pacientes em uso da sibutramina vs
12,9% no grupo placebo e ganho de peso
em 45,2% dos pacientes em uso de
placebo vs 20% no grupo sibutramina.
No grupo sibutramina notamos melhora
dos níveis de HDL-colesterol (aumento
de 17%) e triglicerídeos (diminuição de
12,8%), neste grupo ocorreu também um
aumento da pressão arterial sistólica
(6,7%-5mmHg). Não houve alteração en-
tre os ecocardiogramas do início e final
do acompanhamento e os efeitos adver-
sos não levaram à descontinuação do tra-
tamento.
DISCUSSÃO: A sibutramina mos-
trou-se eficaz na redução de peso, pro-
porcionando um perda de 8% em rela-
ção ao peso inicial. Houve boa adesão
do paciente ao tratamento prolongado,
sem haver descontinuações pelos efei-
tos adversos. Estes dados confirmam o
bom perfil de eficácia, tolerabilidade, e
segurança da sibutramina no tratamen-
to da obesidade.
DESCRIPTORS:  Obesidade. Perda
de peso. Sibutramina.
